Environmental carcinogenesis

Oncology: An Evidence-Based Approach

Volumn , Issue , 2006, Pages 233-243

  Sabo Attwood, T ^a   Ramos Nino, M ^a   Mossman, Brooke T ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890514917     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-31056-8_18     Document Type: Chapter

References (128)

1. Boffetta P, Nyberg F. Contribution of environmental factors to cancer risk. Br Med Bull 2003;68:71-94.
2. National Institute for Environmental Health Sciences (NTP). Tenth Report on Carcinogens. Washington, DC: NTP, 2002.
3. Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med 1998;157 (5 pt 1):1666-1680.
4. Bounias M. Etiological factors and mechanism involved in relationships between pesticide exposure and cancer. J Environ Biol 2003;24(1):1-8.
5. Alavanja MC, Samanic C, Dosemeci M, et al. Use of agricultural pesticides and prostate cancer risk in the Agricultural Health Study cohort. Am J Epidemiol 2003;157(9):800-814.
6. Duell EJ, Millikan RC, Savitz DA, et al. A population-based casecontrol study of farming and breast cancer in North Carolina. Epidemiology 2000;11(5):523-531.
7. Bertazzi PA, Zocchetti C, Guercilena S, et al. Dioxin exposure and cancer risk: a 15-year mortality study after the "Seveso accident." Epidemiology 1997;8(6):646-652.
8. National Institute for Environmental Health Sciences (NTP). Ninth Report on Carcinogens. Washington, DC: NTP, 2001.
9. Sarasin A. An overview of the mechanisms of mutagenesis and carcinogenesis. Mutat Res 2003;544(2-3):99-106.
10. Rubin H. Synergistic mechanisms in carcinogenesis by polycyclic aromatic hydrocarbons and by tobacco smoke: a biohistorical perspective with updates. Carcinogenesis (Oxf) 2001; 22(12):1903-1930.
11. Barrett JC, Shelby MD. Mechanisms of human carcinogens. Prog Clin Biol Res 1992;374:415-434.
12. Rakitsky VN, Koblyakov VA, Turusov VS. Nongenotoxic (epigenetic) carcinogens: pesticides as an example. A critical review. Teratog Carcinog Mutagen 2000;20(4):229-240.
13. Sutherland JE, Costa M. Epigenetics and the environment. Ann NY Acad Sci 2003;983:151-160.
14. Smith LE, Denissenko MF, Bennett WP, et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 2000;92(10):803-811.
15. Vermeulen K, Berneman ZN, Van Bockstaele DR. Cell cycle and apoptosis. Cell Prolif 2003;36(3):165-175.
16. Porta M, Malats N, Jariod M, et al. Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. Lancet 1999; 354(9196):2125-2129.
17. Takahashi M, Barrett JC, Tsutsui T. Transformation by inorganic arsenic compounds of normal Syrian hamster embryo cells into a neoplastic state in which they become anchorage-independent and cause tumors in newborn hamsters. Int J Cancer 2002;99(5):629-634.
18. Cooper K. p53 mutations in human papillomavirus-associated oesophageal squamous cell carcinoma. Br J Cancer 1995; 72(5):1337.
19. Lane DP, Lain S. Therapeutic exploitation of the p53 pathway. Trends Mol Med 2002;8(suppl 4):S38-S42.
20. Hung J, Anderson R. p53: functions, mutations and sarcomas. Acta Orthop Scand Suppl 1997;273:68-73.
21. Cabello G, Juarranz A, Botella LM, Calaf GM. Organophosphorous pesticides in breast cancer progression. J Submicrosc Cytol Pathol 2003;35(1):1-9.
22. Doll R. Nature and nurture: possibilities for cancer control. Carcinogenesis (Oxf) 1996;17(2):177-184.
23. Sorensen M, Autrup H, Moller P, et al. Linking exposure to environmental pollutants with biological effects. Mutat Res 2003;544(2-3):255-271.
24. NIOSH safety and health topic: occupational cancer, CDC, 2004. (Accessed June 2004 at http://www.cdc.gov/niosh/topics/ cancer/).
25. Ward EM, Schulte PA, Bayard S, et al. Priorities for development of research methods in occupational cancer. Environ Health Perspect 2003;111(1):1-12.
26. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981;66(6):1191-1308.
27. Landrigan PJ, Markowitz S. Current magnitude of occupational disease in the United States. Estimates from New York State. Ann NY Acad Sci 1989;572:27-45; discussion 55-60.
28. Leigh JP, Markowitz SB, Fahs M, Shin C, Landrigan PJ. Occupational injury and illness in the United States. Estimates of costs, morbidity, and mortality. Arch Intern Med 1997;157(14): 1557-1568.
29. Kazerouni N, Sinha R, Hsu CH, Greenberg A, Rothman N. Analysis of 200 food items for benzo[a]pyrene and estimation of its intake in an epidemiologic study. Food Chem Toxicol 2001;39(5):423-436.
30. Georgiadis P, Kyrtopoulos SA. Molecular epidemiological approaches to the study of the genotoxic effects of urban air pollution. Mutat Res 1999;428(1-2):91-98.
31. Farmer PB, Singh R, Kaur B, et al. Molecular epidemiology studies of carcinogenic environmental pollutants. Effects of polycyclic aromatic hydrocarbons (PAHs) in environmental pollution on exogenous and oxidative DNA damage. Mutat Res 2003;544(2-3):397-402.
32. McClellan RO. Health effects of exposure to diesel exhaust particles. Annu Rev Pharmacol Toxicol 1987;27:279-300.
33. Fields WR, Desiderio JG, Leonard RM, Burger EE, Brown BG, Doolittle DJ. Differential c-myc expression profiles in normal human bronchial epithelial cells following treatment with benzo[a]pyrene, benzo[a]pyrene-4, 5 epoxide, and benzo[a]pyrene- 7, 8-9, 10 diol epoxide. Mol Carcinog 2004;40(2):79-89.
34. Pohjola SK, Lappi M, Honkanen M, Rantanen L, Savela K. DNA binding of polycyclic aromatic hydrocarbons in a human bronchial epithelial cell line treated with diesel and gasoline particulate extracts and benzo[a]pyrene. Mutagenesis 2003;18(5): 429-438.
35. Li J, Chen H, Ke Q, et al. Differential effects of polycyclic aromatic hydrocarbons on transactivation of AP-1 and NF-kappaB in mouse epidermal cl41 cells. Mol Carcinog 2004;40(2): 104-115.
36. Lau AT, He QY, Chiu JF. A proteome analysis of the arsenite response in cultured lung cells: evidence for in vitro oxidative stress-induced apoptosis. Biochem J 2004;382:641-650.
37. Castano-Vinyals G, D'Errico A, Malats N, Kogevinas M. Biomarkers of exposure to polycyclic aromatic hydrocarbons from environmental air pollution. Occup Environ Med 2004; 61(4):e12.
38. Rappaport SM, Waidyanatha S, Serdar B. Naphthalene and its biomarkers as measures of occupational exposure to polycyclic aromatic hydrocarbons. J Environ Monit 2004;6(5):413-416.
39. Rummel AM, Trosko JE, Wilson MR, Upham BL. Polycyclic aromatic hydrocarbons with bay-like regions inhibited gap junctional intercellular communication and stimulated MAPK activity. Toxicol Sci 1999;49(2):232-240.
40. Yu D, Kazanietz MG, Harvey RG, Penning TM. Polycyclic aromatic hydrocarbon o-quinones inhibit the activity of the catalytic fragment of protein kinase C. Biochemistry 2002; 41(39):11888-11894.
41. Burchiel SW, Luster MI. Signaling by environmental polycyclic aromatic hydrocarbons in human lymphocytes. Clin Immunol 2001;98(1):2-10.
42. Saeki K, Matsuda T, Kato TA, et al. Activation of the human Ah receptor by aza-polycyclic aromatic hydrocarbons and their halogenated derivatives. Biol Pharm Bull 2003;26(4):448-452.
43. Vondracek J, Kozubik A, Machala M. Modulation of estrogen receptor-dependent reporter construct activation and G0/G1-Sphase transition by polycyclic aromatic hydrocarbons in human breast carcinoma MCF-7 cells. Toxicol Sci 2002;70(2):193-201.
44. Marc J, Mulner-Lorillon O, Belle R. Glycophosphate-based pesticides affect cell cycle regulation. Biol Cell 2004;96(3):245-249.
45. Tessier DM, Matsumura F. Increased ErbB-2 tyrosine kinase activity, MAPK phosphorylation, and cell proliferation in the prostate cancer cell line LNCaP following treatment by select pesticides. Toxicol Sci 2001;60(1):38-43.
46. Colborn T, Dumanoski D, Myers J. Our Stolen Future. New York: Penguin, 1997.
47. Hassoun E, Bagchi M, Bagchi D, Stohs SJ. Comparative studies on lipid peroxidation and DNA-single strand breaks induced by lindane, DDT, chlordane and endrin in rats. Comp Biochem Physiol C 1993;104(3):427-431.
48. Frigo DE, Tang Y, Beckman BS, et al. Mechanism of AP-1- mediated gene expression by select organochlorines through the p38 MAPK pathway. Carcinogenesis (Oxf) 2004;25(2):249-261.
49. Shen K, Novak RF. DDT stimulates c-erbB2, c-met, and STATS tyrosine phosphorylation, Grb2-Sos association, MAPK phosphorylation, and proliferation of human breast epithelial cells. Biochem Biophys Res Commun 1997;231(1):17-21.
50. Tseng WP. Effects and dose-response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect 1977;19:109-119.
51. Rossman TG. Mechanism of arsenic carcinogenesis: an integrated approach. Mutat Res 2003;533(1-2):37-65.
52. Guo HR, Wang NS, Hu H, Monson RR. Cell type specificity of lung cancer associated with arsenic ingestion. Cancer Epidemiol Biomarkers Prev 2004;13(4):638-643.
53. Nakadaira H, Endoh K, Katagiri M, Yamamoto M. Elevated mortality from lung cancer associated with arsenic exposure for a limited duration. J Occup Environ Med 2002;44(3):291-299.
54. Shukla A, Gulumian M, Hei TK, Kamp D, Rahman Q, Mossman BT. Multiple roles of oxidants in the pathogenesis of asbestosinduced diseases. Free Radic Biol Med 2003;34(9):1117-1129.
55. Shi H, Shi X, Liu KJ. Oxidative mechanism of arsenic toxicity and carcinogenesis. Mol Cell Biochem 2004;255(1-2):67-78.
56. Harris GK, Shi X. Signaling by carcinogenic metals and metalinduced reactive oxygen species. Mutat Res 2003;533(1-2):183-200.
57. Barchowsky A, O'Hara KA. Metal-induced cell signaling and gene activation in lung diseases. Free Radic Biol Med 2003; 34(9):1130-1135.
58. Frumkin H. Agent Orange and cancer: an overview for clinicians. CA Cancer J Clin 2003;53(4):245-255.
59. Watson MA, Devereux TR, Malarkey DE, Anderson MW, Maronpot RR. H-ras oncogene mutation spectra in B6C3F1 and C57BL/6 mouse liver tumors provide evidence for TCDD promotion of spontaneous and vinyl carbamate-initiated liver cells. Carcinogenesis (Oxf) 1995;16(8):1705-1710.
60. Cole P, Trichopoulos D, Pastides H, Starr T, Mandel JS. Dioxin and cancer: a critical review. Regul Toxicol Pharmacol 2003; 38(3):378-388.
61. Mimura J, Fujii-Kuriyama Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim Biophys Acta 2003;1619(3):263-268.
62. Matsumura F. On the significance of the role of cellular stress response reactions in the toxic actions of dioxin. Biochem Pharmacol 2003;66(4):527-540.
63. Martinez JM, Afshari CA, Bushel PR, Masuda A, Takahashi T, Walker NJ. Differential toxicogenomic responses to 2, 3, 7, 8- tetrachlorodibenzo-p-dioxin in malignant and nonmalignant human airway epithelial cells. Toxicol Sci 2002;69(2):409-423.
64. Guthrie GDJ, Mossman BT. Health effects of mineral dusts. In: Ribbe PH (ed). Mineralogical Society of America. Washington, DC: BookCrafters, 1993.
65. Hazardous Substance Data Bank: Asbestos. National Library of Medicine, NIEHS, 2000. (Accessed June 2004 at http://www. nlm.nih.gov/pubs/factsheets/ hsdbfs.html).
66. MacDonald L. The health hazards of asbestos removal. JAMA 1992;267(1):52-53.
67. Mossman BT, Bignon J, Corn M, Seaton A, Gee JB. Asbestos: scientific developments and implications for public policy. Science 1990;247(4940):294-301.
68. Mossman BT, Gee JB. Asbestos-related diseases. N Engl J Med 1989;320(26):1721-1730.
69. Asbestos: Health effects of exposure to asbestos. ATSDR, 2003. (Accessed June 2004 at http://www.atsdr.cdc.gov/asbestos/ asbestos-effects.html).
70. Craighead JE, Mossman BT. The pathogenesis of asbestosassociated diseases. N Engl J Med 1982;306(24):1446-1455.
71. Fact Sheet FS-012-01, USGS, March 2001. (Accessed June 2003 at http://pubs.usgs.gov/fs/fs012-01/).
72. Asbestos: Asbestos exposure in Libby, Montana. ASTDR, 2003. (Accessed June 2004 at http://www.atsdr.cdc.gov/asbestos/ asbestos-study.html).
73. McDonald JC, Armstrong B, Case B, et al. Mesothelioma and asbestos fiber type. Evidence from lung tissue analyses. Cancer (Phila) 1989;63(8):1544-1547.
74. Langer AM, Nolan RP, Addison J. On talc, tremolite, and tergiversation. Br J Ind Med 1991;48(5):359-360.
75. Roggli VL, Vollmer RT, Butnor KJ, Sporn TA. Tremolite and mesothelioma. Ann Occup Hyg 2002;46(5):447-453.
76. Bernstein DM, Chevalier J, Smith P. Comparison of Calidria chrysotile asbestos to pure tremolite: inhalation biopersistence and histopathology following short-term exposure. Inhal Toxicol 2003;15(14):1387-1419.
77. Craighead J. Airways and lung. In: Pathology of Environmental and Occupational Disease. St. Louis: Mosby, 1995.
78. Roggli VL, Pratt PC, Brody AR. Asbestos fiber type in malignant mesothelioma: an analytical scanning electron microscopic study of 94 cases. Am J Ind Med 1993;23(4):605-614.
79. McDonald JC. Cancer risks due to asbestos and man-made fibres. Recent Results Cancer Res 1990;120:122-131.
80. McDonald JC, McDonald AD, Armstrong B, Sebastien P. Cohort study of mortality of vermiculite miners exposed to tremolite. Br J Ind Med 1986;43(7):436-444.
81. Hammond EC, Selikoff IJ, Seidman H. Asbestos exposure, cigarette smoking and death rates. Ann NY Acad Sci 1979;330: 473-490.
82. Saracci R. The interactions of tobacco smoking and other agents in cancer etiology. Epidemiol Rev 1987;9:175-193.
83. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960;17:260-271.
84. Grondin SC, Sugarbaker DJ. Malignant mesothelioma of the pleural space. Oncology (Huntingt) 1999;13(7):919-926; discussion 26, 31-32.
85. Grondin S, Sugarbaker D. Malignant mesothelioma of the pleural space. Oncology 1999;13(7):919-926.
86. Boutin C, Schlesser M, Frenay C, Astoul P. Malignant pleural mesothelioma. Eur Respir J 1998;12(4):972-981.
87. Churg A. Chrysotile, tremolite, and malignant mesothelioma in man. Chest 1988;93(3):621-628.
88. Yano E, Wang ZM, Wang XR, Wang MZ, Lan YJ. Cancer mortality among workers exposed to amphibole-free chrysotile asbestos. Am J Epidemiol 2001;154(6):538-543.
89. Vu VT, Lai DY. Approaches to characterizing human health risks of exposure to fibers. Environ Health Perspect 1997; 105S(suppl 5):1329-1336.
90. Asbestos in public and commercial buildings: a literature reviewed synthesis of current knowledge. Cambridge, MA: Health Effects Institute-Asbestos Research, 1991. (Accessed June 2003 at http://www.asbestos-institute.ca/ reviews/hei-ar/hei-ar. html).
91. Jaurand MC, Gaudichet A, Halpern S, Bignon J. In vitro biodegradation of chrysotile fibres by alveolar macrophages and mesothelial cells in culture: comparison with a pH effect. Br J Ind Med 1984;41(3):389-395.
92. Woodworth CD, Mossman BT, Craighead JE. Induction of squamous metaplasia in organ cultures of hamster trachea by naturally occurring and synthetic fibers. Cancer Res 1983;43(10): 4906-4912.
93. Mossman BT, Kamp DW, Weitzman SA. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Invest 1996;14(5):466-480.
94. Shukla A, Jung M, Stern M, et al. Asbestos induces mitochondrial DNA damage and dysfunction linked to the development of apoptosis. Am J Physiol Lung Cell Mol Physiol 2003;285(5): L1018-L1025.
95. Kamp DW, Graceffa P, Pryor WA, Weitzman SA. The role of free radicals in asbestos-induced diseases. Free Radic Biol Med 1992;12(4):293-315.
96. Hansen K, Mossman BT. Generation of superoxide (O2 -.) from alveolar macrophages exposed to asbestiform and nonfibrous particles. Cancer Res 1987;47(6):1681-1686.
97. Fang R, Aust AE. Induction of ferritin synthesis in human lung epithelial cells treated with crocidolite asbestos. Arch Biochem Biophys 1997;340(2):369-375.
98. Chao CC, Lund LG, Zinn KR, Aust AE. Iron mobilization from crocidolite asbestos by human lung carcinoma cells. Arch Biochem Biophys 1994;314(2):384-391.
99. Janssen YM, Van Houten B, Borm PJ, Mossman BT. Cell and tissue responses to oxidative damage. Lab Invest 1993;69(3): 261-274.
100. Kinnula VL. Oxidant and antioxidant mechanisms of lung disease caused by asbestos fibres. Eur Respir J 1999;14(3): 706-716.
101. Murthy SS, Testa JR. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 1999;180(2):150-157.
102. Fung H, Kow YW, Van Houten B, Mossman BT. Patterns of 8- hydroxydeoxyguanosine formation in DNA and indications of oxidative stress in rat and human pleural mesothelial cells after exposure to crocidolite asbestos. Carcinogenesis (Oxf) 1997; 18(4):825-832.
103. Pass HI, Mew DJ. In vitro and in vivo studies of mesothelioma. J Cell Biochem Suppl 1996;24:142-151.
104. Churg A. The uptake of mineral particles by pulmonary epithelial cells. Am J Respir Crit Care Med 1996;154(4 pt 1):1124-1140.
105. Janssen YM, Barchowsky A, Treadwell M, Driscoll KE, Mossman BT. Asbestos induces nuclear factor kappa B (NFkappa B) DNA-binding activity and NF-kappa B-dependent gene expression in tracheal epithelial cells. Proc Natl Acad Sci USA 1995;92(18):8458-8462.
106. Ramos-Nino ME, Haegens A, Shukla A, Mossman BT. Role of mitogen-activated protein kinases (MAPK) in cell injury and proliferation by environmental particulates. Mol Cell Biochem 2002;234-235(1-2):111-118.
107. Ramos-Nino ME, Timblin CR, Mossman BT. Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res 2002;62(21): 6065-6069.
108. Kahlos K, Pitkanen S, Hassinen I, Linnainmaa K, Kinnula VL. Generation of reactive oxygen species by human mesothelioma cells. Br J Cancer 1999;80(1-2):25-31.
109. Goldberg JL, Zanella CL, Janssen YM, et al. Novel cell imaging techniques show induction of apoptosis and proliferation in mesothelial cells by asbestos. Am J Respir Cell Mol Biol 1997; 17(3):265-271.
110. Broaddus VC, Yang L, Scavo LM, Ernst JD, Boylan AM. Asbestos induces apoptosis of human and rabbit pleural mesothelial cells via reactive oxygen species. J Clin Invest 1996;98(9):2050-2059.
111. BeruBe KA, Quinlan TR, Fung H, et al. Apoptosis is observed in mesothelial cells after exposure to crocidolite asbestos. Am J Respir Cell Mol Biol 1996;15(1):141-147.
112. Kamp DW, Panduri V, Weitzman SA, Chandel N. Asbestosinduced alveolar epithelial cell apoptosis: role of mitochondrial dysfunction caused by iron-derived free radicals. Mol Cell Biochem 2002;234-235(1-2):153-160.
113. Laveck MA, Somers AN, Moore LL, Gerwin BI, Lechner JF. Dissimilar peptide growth factors can induce normal human mesothelial cell multiplication. In Vitro Cell Dev Biol 1988; 24(11):1077-1084.
114. Mossman BT, Gruenert DC. SV40, growth factors, and mesothelioma: another piece of the puzzle. Am J Respir Cell Mol Biol 2002;26(2):167-170.
115. Pache JC, Janssen YM, Walsh ES, et al. Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers. Am J Pathol 1998;152(2): 333-340.
116. Zanella CL, Posada J, Tritton TR, Mossman BT. Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res 1996;56(23): 5334-5338.
117. Faux SP, Houghton CE, Hubbard A, Patrick G. Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres. Carcinogenesis (Oxf) 2000;21(12):2275-2280.
118. Heintz NH, Janssen YM, Mossman BT. Persistent induction of c-fos and c-jun expression by asbestos. Proc Natl Acad Sci USA 1993;90(8):3299-3303.
119. Reddy SP, Mossman BT. Role and regulation of activator protein- 1 in toxicant-induced responses of the lung. Am J Physiol Lung Cell Mol Physiol 2002;283(6):L1161-L1178.
120. Sandhu H, Dehnen W, Roller M, Abel J, Unfried K. mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats. Carcinogenesis (Oxf) 2000;21(5):1023-1029.
121. Walker C, Everitt J, Ferriola PC, Stewart W, Mangum J, Bermudez E. Autocrine growth stimulation by transforming growth factor alpha in asbestos-transformed rat mesothelial cells. Cancer Res 1995;55(3):530-536.
122. Rutten AA, Bermudez E, Stewart W, Everitt JI, Walker CL. Expression of insulin-like growth factor II in spontaneously immortalized rat mesothelial and spontaneous mesothelioma cells: a potential autocrine role of insulin-like growth factor II. Cancer Res 1995;55(16):3634-3639.
123. Metheny-Barlow LJ, Flynn B, van Gijssel HE, Marrogi A, Gerwin BI. Paradoxical effects of platelet-derived growth factor-A overexpression in malignant mesothelioma. Antiproliferative effects in vitro and tumorigenic stimulation in vivo. Am J Respir Cell Mol Biol 2001;24(6):694-702.
124. Adamson IY, Bakowska J. KGF and HGF are growth factors for mesothelial cells in pleural lavage fluid after intratracheal asbestos. Exp Lung Res 2001;27(7):605-616.
125. Cacciotti P, Libener R, Betta P, et al. SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci USA 2001;98(21):12032-12037.
126. Ramos-Nino ME, Scapoli L, Martinelli M, Land S, Mossman BT. Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. Cancer Res 2003;63(13): 3539-3545.
127. Mossman B, Klein G, zur Hausen H. Modern criteria to determine the etiology of human carcinogens. Semin Cancer Biol (in press).
128. Chase K, Whysner J, Shields P. Clinics in Occupational and Environmental Medicine. Carcinogens in the Workplace. Philadelphia: Saunders, 2003.